Vontobel Holding Ltd. Takes $262,000 Position in Takeda Pharmaceutical Co. (NYSE:TAK)

Vontobel Holding Ltd. purchased a new stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,619 shares of the company's stock, valued at approximately $262,000.

Several other large investors have also recently bought and sold shares of TAK. Blair William & Co. IL boosted its position in Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after purchasing an additional 913 shares during the period. Vise Technologies Inc. lifted its holdings in Takeda Pharmaceutical by 3.1% during the 4th quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock worth $459,000 after purchasing an additional 1,026 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after purchasing an additional 1,045 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Takeda Pharmaceutical by 5.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock worth $319,000 after purchasing an additional 1,098 shares during the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock worth $105,000 after purchasing an additional 1,296 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Performance

NYSE:TAK traded down $0.17 during mid-day trading on Friday, hitting $14.67. 3,165,167 shares of the stock were exchanged, compared to its average volume of 2,001,622. The stock has a market capitalization of $46.68 billion, a price-to-earnings ratio of 9.29 and a beta of 0.23. The firm's 50-day simple moving average is $14.84 and its 200 day simple moving average is $14.38. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.52 and a current ratio of 1.01. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.53.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). The company had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. As a group, equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.